Reports from Yale University Add New Data to Findings in Type 1 Diabetes (Teplizumab Induces Persistent Changes In the Antigen- Specific Repertoire In Individuals At Risk for Type 1 Diabetes).

A recent study conducted at Yale University focused on the effects of Teplizumab, a drug used to delay the progression of type 1 diabetes in at-risk patients. The research found that after 5 years, 36% of participants remained free of clinical diabetes, suggesting operational tolerance. The study analyzed changes in the antigen-specific repertoire of T cells in response to Teplizumab treatment, indicating a promotion of operational tolerance and prevention of expansion of autoreactive T cells. [Extracted from the article]